| Zacks Company Profile for Arcutis Biotherapeutics, Inc. (ARQT : NSDQ) |
|
|
| |
| • Company Description |
| Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.
Number of Employees: 342 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $20.91 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,052,884 shares |
| Shares Outstanding: 119.90 (millions) |
| Market Capitalization: $2,507.22 (millions) |
| Beta: 2.06 |
| 52 Week High: $21.84 |
| 52 Week Low: $8.03 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
18.07% |
18.12% |
| 12 Week |
39.21% |
33.63% |
| Year To Date |
50.11% |
33.18% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
3027 TOWNSGATE ROAD SUITE 300
-
WESTLAKE VILLAGE,CA 91361
USA |
ph: 805-418-5006
fax: - |
ir@arcutis.com |
http://www.arcutis.com |
|
|
| |
| • General Corporate Information |
Officers
Todd Franklin Watanabe - President; Chief Executive Officer and Director
Keith R. Leonard - Director; Chairman
David Topper - Chief Financial Officer
Bhaskar Chaudhuri - Director
Terrie Curran - Director
|
|
Peer Information
Arcutis Biotherapeutics, Inc. (CORR.)
Arcutis Biotherapeutics, Inc. (RSPI)
Arcutis Biotherapeutics, Inc. (CGXP)
Arcutis Biotherapeutics, Inc. (BGEN)
Arcutis Biotherapeutics, Inc. (GTBP)
Arcutis Biotherapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969K108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 10/28/25
|
|
Share - Related Items
Shares Outstanding: 119.90
Most Recent Split Date: (:1)
Beta: 2.06
Market Capitalization: $2,507.22 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.05 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.44 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 10/28/25 |
|
|
|
| |
